AOTI’s TWO2® Therapy Gains NICE Recommendation and NHS Framework Inclusion

AOTI, Inc. ( (GB:AOTI) ) just unveiled an announcement.

AOTI, Inc. announced that its Topical Wound Oxygen (TWO2®) therapy is now included in the NICE guidelines for diabetic foot problems and is active on the NHS Supply Chain’s Advanced Wound Care Framework. This inclusion allows for accelerated marketing and easier access for NHS organizations, potentially improving patient outcomes and reducing healthcare costs. The recognition by NICE and the NHS framework is a significant step forward for AOTI, enhancing its market position and validating its clinical value proposition.

The most recent analyst rating on (GB:AOTI) stock is a Hold with a £66.00 price target. To see the full list of analyst forecasts on AOTI, Inc. stock, see the GB:AOTI Stock Forecast page.

Spark’s Take on GB:AOTI Stock

According to Spark, TipRanks’ AI Analyst, GB:AOTI is a Neutral.

The overall score reflects a mix of positive corporate events and challenges in financial performance and valuation. Insider confidence and strategic milestones are offset by bearish technical signals and lack of profitability.

To see Spark’s full report on GB:AOTI stock, click here.

More about AOTI, Inc.

AOTI, Inc., founded in 2006 and based in Oceanside, California, and Galway, Ireland, specializes in innovative solutions for severe and chronic wounds. The company’s flagship product, Topical Wound Oxygen (TWO2®) therapy, is a non-invasive treatment that has shown significant efficacy in reducing hospitalizations and amputations related to Diabetic Foot Ulcers. The therapy is approved by regulatory bodies in the US, Europe, UK, Canada, China, Australia, and Saudi Arabia.

Average Trading Volume: 340,108

Technical Sentiment Signal: Strong Sell

Current Market Cap: £58.5M

For an in-depth examination of AOTI stock, go to TipRanks’ Overview page.